Study of two drugs for advanced ovarian clear cell cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests two investigational drugs, alone or together, for advanced ovarian clear cell cancer that has not responded to usual treatments. The goal is to see if these drugs help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of pure ovarian clear cell cancer
- You have already tried at least one standard chemotherapy regimen and one immunotherapy
- You are generally able to care for yourself (performance status 0 or 1)
- You have a tumor sample available for review
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs — liposomal irinotecan (a type of chemotherapy), sintilimab (an immunotherapy that helps your immune system fight cancer), and anlotinib (a targeted therapy that blocks blood vessels feeding the tumor) — for women with ovarian clear cell carcinoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink or control the cancer better than existing options.
This study looks at a drug called sacituzumab for people with a rare type of ovarian cancer (clear cell carcinoma) that has not responded to immunotherapy. The goal is to see if sacituzumab is safe and effective for these patients.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
This trial tests two targeted drugs — sacituzumab tirumotecan (which attacks cancer cells) and bevacizumab (which cuts off blood supply to tumors) — for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination helps shrink or slow the cancer.
Hear when a new Ovarian Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.